300pc poker game set Michigan athletic director Warde Manuel gets 5-year contract extensionPHILADELPHIA - Joel Embiid has missed 16 games this season because of left knee injury management, knee swelling, personal reasons and a three-game suspension. After missing his 17th contest against the Orlando Magic, the 2023 NBA MVP will wade into dangerous territory and risk disqualification for regular-season awards. The NBA, in cooperation with the National Basketball Players Association, instituted a 65-game rule last season for awards, aiming to deter players and teams from relying on load management to skip games. The seven-time All-Star was disqualified last season after playing in only 39 games. This season, the most games Embiid can play is 65, provided he participates in all remaining contests starting with Sunday’s game against the Bulls in Chicago. However, that scenario is unlikely, as Embiid is not expected to play on back-to-back nights due to load management. Embiid, who has missed the last six games, is averaging career lows of 19.8 points, 7.5 rebounds and 1.0 block. He’s also posting career lows of 37.9% shooting from the field and 16.7% from 3-point range. While Embiid will remain sidelined, Paul George is set to return after missing one game for load management to face the Magic (16-8) at the Wells Fargo Center. Meanwhile, center Andre Drummond (sprained right ankle) has been upgraded to questionable after being initially ruled out. His status change could be related to reserve center Adem Bona being sidelined with a bruised left knee. The Sixers (5-15) will look to avenge Wednesday’s 106-102 loss to Orlando.

NEW YORK , Dec. 5, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Arch Resources, Inc. (NYSE: ARCH ), relating to its proposed merger with Consol Energy, Inc. Under the terms of the agreement, all Arch Resources common stock will be automatically converted into the right to receive 1.326 shares of Consol Energy stock. ACT NOW . The Shareholder Vote is scheduled for January 9, 2025 . Click here for more information https://monteverdelaw.com/case/arch-resources-inc/ . It is free and there is no cost or obligation to you. Universal Stainless & Alloy Products Inc. (Nasdaq: USAP ), relating to its proposed merger with Aperam US Absolute LLC. Under the terms of the agreement, all USAP shares will be automatically converted into the right to receive $45.00 per share. ACT NOW. The Shareholder Vote is scheduled for January 15, 2025 . Click here for more information https://monteverdelaw.com/case/universal-stainless-alloy-products-inc/ . It is free and there is no cost or obligation to you. Cyclo Therapeutics, Inc. (Nasdaq: CYTH ), relating to its proposed merger with Rafael Holdings, Inc. Under the terms of the agreement, Cyclo common stock will automatically be converted into the right to receive shares of Rafael common stock. Click here for more information https://monteverdelaw.com/case/cyclo-therapeutics-inc/ . It is free and there is no cost or obligation to you. BurTech Acquisition Corp. (NASDAQ: BRKH ) , relating to the proposed merger with Blaize, Inc. Under the terms of the agreement, shares of BurTech Acquisition will be exchanged for shares of Blaize. ACT NOW. The Shareholder Vote is scheduled for December 23, 2024 . Click here for more information https://monteverdelaw.com/case/burtech-acquisition-corp-brkh/ . It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: About Monteverde & Associates PC Our firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No company, director or officer is above the law. If you own common stock in any of the above listed companies and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 Attorney Advertising. (C) 2024 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC ( www.monteverdelaw.com ). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde & Associates PC

TORONTO , Dec. 5, 2024 /CNW/ - Franklin Templeton Canada today announced the final distributions, final net asset value (NAV) and net proceeds for Franklin International Multifactor Index ETF (FLDM), Franklin Global Dividend Quality Index ETF (FLGD) and Franklin Western Asset Core Plus Bond Fund - ETF series (FWCP). FLDM, FLGD and FWCP were voluntarily delisted from the Toronto Stock Exchange (TSX) as of market close on November 29, 2024 , and have been terminated at the close of business on December 4 , 2024. The ETF terminations were previously announced on September 25, 2024 . In preparation for the ETF terminations, Franklin Templeton Canada has converted FLDM, FLGD and FWCP's holdings to cash (in Canadian dollars), and the remaining assets — after paying or providing for the ETFs' liabilities and obligations —will be distributed to the ETFs' unitholders on a pro rata basis as detailed in the table below. Terminating Fund Ticker Final NAV Per Unit ($) Net Proceeds Per Unit ($) Franklin International Multifactor Index ETF FLDM 22.9363305 22.9363305 Franklin Global Dividend Quality Index ETF FLGD 29.7028696 29.7028696 Franklin Western Asset Core Plus Bond Fund - ETF series FWCP 17.378160 17.378160 Each fund's unitholders of record as of December 3, 2024 , will receive the final cash distribution (in Canadian dollars) as detailed in the table below. These final distributions replace the estimated distributions provided on November 26, 2024 . Terminating Fund Ticker Income Distribution Per Unit ($) Capital Gain Distribution Per Unit ($) Total Cash Distribution Per Unit ($) Franklin International Multifactor Index ETF FLDM 0.558212 - 0.558212 Franklin Global Dividend Quality Index ETF FLGD - - - Franklin Western Asset Core Plus Bond Fund - ETF series FWCP - - - About Franklin Templeton Franklin Resources, Inc. BEN is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. In Canada, the company's subsidiary is Franklin Templeton Investments Corp., which operates as Franklin Templeton Canada . Franklin Templeton's mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,500 investment professionals, and offices in major financial markets around the world, the California -based company has over 75 years of investment experience and over US$1.6 trillion (over CAN$2.2 trillion) in assets under management as of November 30, 2024 . For more information, please visit franklintempleton.ca and connect with Franklin Templeton on LinkedIn , X and Facebook . Commissions, management fees and expenses all may be associated with investments in ETFs and ETF series. Investors should carefully consider an ETF's and ETF series' investment objectives and strategies, risks, fees and expenses before investing. The prospectus and ETF facts contain this and other information. Please read the prospectus and ETF facts carefully before investing. ETFs and ETF series trade like stocks, fluctuate in market value and may trade at prices above or below their net asset value. Brokerage commissions and ETF and ETF series expenses will reduce returns. ETFs and ETF series are not guaranteed, their values change frequently, and past performance may not be repeated. Copyright © 2024. Franklin Templeton. All rights reserved. SOURCE Franklin Templeton Investments Corp. View original content: http://www.newswire.ca/en/releases/archive/December2024/05/c1951.html © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Informa TechTarget ("Informa" or the "Company") (NASDAQ: TTGT ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Informa and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On December 2, 2024 , TechTarget completed its business combination with Informa Tech, a business unit of Informa PLC ("Informa"). Then, on December 6, 2024 Tech Target disclosed in a filing with the U.S. Securities and Exchange Commission that Informa's management had advised the Company that certain "financial statements previously prepared by Informa should no longer be relied upon and were being restated because of errors identified by Informa in such financial statements". On this news, TechTarget's stock price fell $2.06 per share, or 8.07%, to close at $23.48 per share on December 9, 2024 . Pomerantz LLP, with offices in New York , Chicago , Los Angeles , London , Paris , and Tel Aviv , is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud , breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com . Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP

Hegseth meets with moderate Sen. Collins as he lobbies for key votes in the Senate

FSK Completes Public Offering of $100 million 6.125% Unsecured Notes Due 2030Michigan athletic director Warde Manuel gets 5-year contract extensionMichigan athletic director Warde Manuel gets 5-year contract extension

TAMPA, Fla. — Baker Mayfield rubbed both arms with his hands as the story was being related, the one where his timely donation turned around the fortunes of a high school football team that lacked the necessary equipment to start the season. It’s the nearly made-for-Hollywood script of how Space Coast High in Cocoa went from 1-8 a year ago to 10-3 and the first state championship in program history. “I’ve got chills thinking about it,” Mayfield said. Jake Owens had been Space Coast’s head coach from 2012-17 but stepped away for a few years, moving to Kentucky and starting a young family. He returned to his old job to find the program in disrepair. “Obviously, the program was struggling,” Owens said. “I think in those six years they’d only won, like, four games. When I walked in, a struggling program like that, nothing was really being done behind the scenes as far as equipment and stuff goes. It was a lot of older equipment.” Stephanie Starkey, whose son, Jacob, plays linebacker and long snapper for the Vipers, graduated from the University of Oklahoma and had followed Mayfield closely. She knew about the Baker and Emily Mayfield Foundation, and reached out to the couple for help. The Mayfields responded by donating $17,900 for equipment, including 70 Riddell SpeedFlex helmets that retail for nearly $500 each, along with shoulder pads. “There was kind of narrative that we were not going to have a season,” Owens said. “That’s not the case. We were going to play no matter what. But it was in bad shape, and that’s obviously expensive. When the program ended last year, there were only 40-something kids. They didn’t have a need for a lot of equipment. “When I took over in February, there was a huge influx. We had over 70 kids come out. Not only did we have older equipment, but we also didn’t have enough. We were going to make sure we had it one way or another, but it’s expensive and funds are hard to come by in high school.” The team was among the youngest Owens had ever coached. His quarterback was a freshman. Four of the five offensive linemen were sophomores, along with the top receiver. Building a culture of winning is usually the most difficult task for any head coach. But Owens said the players were galvanized by the fact that an NFL quarterback had invested so generously in their future. “We were just floored,” Owens said. “It’s been an incredibly humbling experience to have someone like Baker to reach out and say, ‘Hey, what do you need to get this done?’ I don’t think they know how much of an impact they’ve made. “We knew we had a talented team. We knew if we did things the right way and we built the right culture, I’d won there before. I have an incredible coaching staff. They knew what it takes to win. It’s one of those incredible things that came together like a perfect storm, and Baker and Emily are a big part of that because it took so much stress out of that situation so the focus could be on football.” There is some irony that it was Mayfield who rescued the Vipers. Owens is an unabashed Cincinnati Bengals fan and rooted against Mayfield when he played for the Cleveland Browns. In fact, Owens is a Bengals season ticket holder who still hosts a podcast dedicated to talking about the team. “I will tell you that I have never rooted for another team or another player outside of Cincinnati,” Owens said. “That changed after this year. I’ve become a huge Baker Mayfield fan. He changes people’s lives. “At the end of the day, winning is very important at every level. What Baker has done more than anything is shown our players what it means to pass it along. To pay it forward. That’s going to impact our players. When they get that opportunity, they will remember that. What they’ve shown our boys is you’re never too big to help out.” Mayfield’s play on the field was inspiring as well. Starkey held a few watch parties for Bucs games on Sundays. The Mayfields’ gift ignited a Space Coast team that went 7-3 in the regular season, then advanced past Tradition Prep and Umatilla in the playoffs. “Snake Pit” signs, referencing the team’s home field, started popping up on lawns and in store windows all over town. Last weekend, the Vipers defeated Bell, 21-14, at home to claim the Sunshine State Athletic Association Atlantic 1A championship. The team that didn’t have enough equipment is now being sized for championship rings. “I tell them all the time, don’t forget about the journey it took to get here, and Baker and Emily will always be part of that journey,” Owens said. Standing inside One Buc Place during his weekly news conference Thursday, Mayfield could not stop smiling while thinking about another football team he already had helped win a championship this season. “It’s just a cool story,” he said. “I have an unbelievable platform to be able to give back, and obviously they were in the predicament of probably not having a season. Not just for the varsity. The JV, they didn’t have enough equipment. So, just being able to give back and then seeing that turn around. “All we did was get some helmets. They did the rest. They turned it around, they believed in it, and that’s what football is all about. It’s teaching life lessons, how to handle adversity, how to deal with it and push forward. Congrats to them. It’s pretty special.” ©2024 Tampa Bay Times. Visit tampabay.com . Distributed by Tribune Content Agency, LLC.NEW YORK , Dec. 5, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The clinical trials market in US size is estimated to grow by USD 5 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 4.38% during the forecast period. Rise in number of clinical trials of drugs is driving market growth, with a trend towards advancement in technology and scientific research. However, rise in cost of clinic trials poses a challenge. Key market players include Accell Clinical Research LLC, Apex Medical Research Inc., Caidya, Charles River Laboratories International Inc., Clinipace Inc., CTI Clinical Trial and Consulting Inc., Eli Lilly and Co., eResearchTechnology GmbH, ICON plc, IQVIA Holdings Inc., Laboratory Corp. Of America Holdings, Medpace Holdings Inc., Novartis AG, Novo Nordisk AS, Parexel International Corp., Pfizer Inc., Sanofi SA, Syneos Health Inc., Thermo Fisher Scientific Inc., and WuXi AppTec Co. Ltd.. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Forecast period 2024-2028 Base Year 2023 Historic Data 2017 - 2021 Segment Covered Type (Phase III, Phase I, Phase II, and Phase IV), Service Type (Interventional studies, Observational studies, and Expanded access studies), Indication (Oncology, CNS, Autoimmune/inflammation, and Others), and Geography (North America) Region Covered US Key companies profiled Accell Clinical Research LLC, Apex Medical Research Inc., Caidya, Charles River Laboratories International Inc., Clinipace Inc., CTI Clinical Trial and Consulting Inc., Eli Lilly and Co., eResearchTechnology GmbH, ICON plc, IQVIA Holdings Inc., Laboratory Corp. Of America Holdings, Medpace Holdings Inc., Novartis AG, Novo Nordisk AS, Parexel International Corp., Pfizer Inc., Sanofi SA, Syneos Health Inc., Thermo Fisher Scientific Inc., and WuXi AppTec Co. Ltd. Key Market Trends Fueling Growth The Clinical Trials Market in the US is experiencing significant growth, driven by biopharmaceutical and medical device companies seeking to bring new drug candidates to market. Contract Research Organizations (CROs) play a crucial role in this process, providing essential services to pharmaceutical companies during all phases of clinical research, from Phase I to IV. This includes working with healthcare workers to conduct studies on various diseases such as cardiology, autoimmune, inflammation, pain management, oncology, CNS conditions, diabetes, obesity, and cardiovascular conditions. Technological evolution is a key trend in the market, with the use of AI, IoT, real-world data, patient-centric trials, virtual trials, and home healthcare services driving digitalization. The demand for CROs is high, with companies like Parexel and Syneos Health leading the way in providing CRO services. Small-molecule drugs, biologics, biosimilars, and large-molecule drugs are all under development, with raw material suppliers and laboratory services supporting research activities. The industry is at a growth stage, with R&D programs and outsourcing activities expanding. The European Medicines Agency and other regulatory bodies are also playing a role in the market, with an increased focus on personalized medicine and advanced therapies. Patent expiration is leading to an increased focus on post-marketing surveillance. The degree of innovation is high, with big data analytics, remote monitoring, and electronic data capture driving progress. End-users include hospitals and clinics, with virtual clinical trials, interventional studies, expanded access trials, and compassionate use trials also playing a role. Industries like Thermo Fisher Scientific and CorEvitas, LLC are contributing to the market with their expertise in various areas. The clinical trials market in the US has experienced substantial progress due to technological and scientific advancements. Notable developments include the implementation of electronic data capture (EDC) systems. EDC platforms streamline and enhance clinical trial data management. Researchers can now electronically record data from study participants, eliminating the need for paper-based systems and manual data entry. This leads to time savings, reduced errors, and improved data quality. EDC systems play a crucial role in the efficient and effective testing and approval of new medications and therapies. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! Insights into how AI is reshaping industries and driving growth- Download a Sample Report This clinical trials market in US report extensively covers market segmentation by 1.1 Phase III- The Phase III segment of clinical trials in the US plays a crucial role in testing the safety and efficacy of new drugs or medical treatments before they are approved for public use. This phase is the final step in the drug development process and involves testing the investigational treatment on a larger population to gather more data and assess potential benefits and risks. For instance, a new cancer drug that has already undergone rigorous testing in Phase I and II trials will enter Phase III trials, where it is administered to a larger group of cancer patients. The trial aims to gather more evidence on the drug's safety profile, dosage, side effects, and long-term outcomes. Phase III trials involve hundreds or even thousands of participants spread across multiple trial sites in the country. These trials are meticulously planned, ethically conducted, and require data management systems. Regulatory authorities, such as the US Food and Drug Administration (FDA), rely on the data from Phase III trials to evaluate the safety and effectiveness of new treatments and make informed decisions about their approval. The growing demand for new treatments and the increasing focus on personalized medicine are expected to drive the growth of the Phase III clinical trials market in the US during the forecast period. Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2017 - 2021) The Clinical Trials Market in the US is experiencing significant growth due to the increasing number of biopharmaceutical and medical device companies investing heavily in Research & Development (R&D) for new drug candidates and medical devices. Clinical research organizations (CROs) and laboratories play a crucial role in conducting clinical trials for these companies. The focus on patient-centric trials, virtual trials, and real-world data is transforming the clinical trials landscape. Technological advancements such as genomics, Artificial Intelligence (AI), Internet of Things (IoT), and digital health are revolutionizing the way trials are conducted. Small-molecule drugs and biologics continue to dominate the market, with Interferon-beta treatment being a notable example. The technological evolution of clinical trials is enabling faster and more efficient trial processes, benefiting both healthcare workers and patients alike. Traditional clinical trials are being supplemented with innovative approaches to address the challenges of recruiting and retaining patients, ensuring data accuracy, and reducing trial costs. The Clinical Trials Market in the US is a dynamic and evolving industry, driven by the research and development (R&D) activities of biopharmaceutical companies and medical device manufacturers. The market encompasses various stakeholders including clinical research organizations (CROs), healthcare workers, and end-users such as hospitals and clinics. The pipeline includes drug candidates ranging from small-molecule drugs to biologics and biosimilars, with a focus on indications like autoimmune, inflammation, pain management, oncology, CNS conditions, diabetes, obesity, and cardiovascular diseases. Technological advancements, such as genomics, AI, IoT, real-world data, patient-centric trials, virtual trials, home healthcare services, digitalization, and electronic data capture, are transforming the landscape. The industry is in a growth stage, with a high demand for CRO services, decentralized trials, telemedicine, and advanced therapies. The European Medicines Agency and regulatory bodies play a crucial role in post-marketing surveillance. The degree of innovation is high, with a focus on personalized medicine, R&D programs, outsourcing activities, and patent expiration. Key trends include the use of interventional studies, expanded access trials, compassionate use trials, and the evolution of traditional clinical trials towards more decentralized and virtual models. Companies like Parexel, Syneos Health, Thermo Fisher Scientific, and CorEvitas, LLC are at the forefront of these developments. 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.com Website: www.technavio.com/ View original content to download multimedia: https://www.prnewswire.com/news-releases/clinical-trials-market-in-the-us-to-grow-by-usd-5-billion-from-2024-2028-driven-by-more-drug-trials-with-ai-redefining-market-trends---technavio-302322432.html SOURCE Technavio

Oscar Fairs from Benfleet, Essex, was diagnosed with a rare 7cm ependymoma brain tumour in August 2023 and underwent seven surgeries, one round of chemotherapy and one round of radiotherapy to be told palliative care was the only option. A GoFundMe page was set up to help the family raise £100,000 towards a treatment trial in France. It is with deep and profound sadness that West Ham United confirm the tragic passing of our U15s Academy goalkeeper Oscar Fairs, following his brave battle with cancer. Rest in peace, brave Oscar. — West Ham United (@WestHam) December 13, 2024 West Ham footballers donated £27,000, chairman David Sullivan donated £10,000 and Arsenal footballer and former West Ham star Declan Rice gave £5,000, according to Ms Fairs. On Friday, West Ham announced that the 15-year-old had died. Sporting director Mark Noble said: “Oscar was adored by everyone at the Academy – not only was he a great goalkeeper, he was a true Hammer and a fantastic young person, who will be deeply missed by everyone who had the pleasure to know him. “I have wonderful memories of Oscar playing in my garden – (my son) Lenny and his teammates all loved him. “He was a friendly, happy, well-mannered and polite young man, who had such a bright future ahead of him, and it is just so unimaginably devastating that he has been taken from his family and friends at this age. “The thoughts and sincere condolences of everyone at the Club are with Oscar’s parents, Natalie and Russell, and his brother Harry, and we kindly ask that the family’s privacy is respected at this extremely difficult time.” All scheduled Academy fixtures over the weekend have been postponed as a mark of respect.PORTLAND, Maine (AP) — A pair of conservative groups on Friday challenged a Maine law that limits donations to political action committees that spend independently in candidate elections, arguing that money spent to support political expression is "a vital feature of our democracy.” Supporters of the referendum overwhelmingly approved on Election Day fully expected a legal showdown over caps on individual contributions to so-called super PACs. They hoped the referendum would trigger a case and ultimately prompt the U.S. Supreme Court to clarify the matter of donor limits after the court opened the floodgates to independent spending in its 2010 Citizens United decision. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Canadian telecoms monitoring networks amid massive cyberespionage campaign from China

Fleet Space raises $150m for minerals exploration ambitions